Plain-English translation of NCT07239115 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This is a large study testing whether , a medication commonly used to prevent seizures, can reduce seizure risk in patients having brain tumor surgery. About two-thirds of brain tumor patients develop seizures after surgery, but doctors don't know for certain whether giving the medication to everyone before surgery truly prevents them. This trial will help answer that question by comparing patients who receive the medication with those who receive a placebo (inactive treatment).
Seizures are a major complication after brain tumor surgery, but major medical organizations don't have enough evidence to recommend routine prevention for all patients. This study will provide clear, reliable data to guide doctors on whether this medication should be standard treatment for everyone having this type of brain surgery.
You likely qualify if…
You likely don't qualify if…
If you join, you'll receive either the medication or a placebo that looks identical — neither you nor your doctors will know which at first. You'll get an intravenous dose 1 hour before surgery and another dose the evening after surgery, then take pills twice daily for 3 months. You'll have follow-up visits at 1 week, 3 months, and 6 months after surgery, where doctors will check for any seizures and perform routine brain scans and electrical monitoring (EEG) tests.
AI-generated summary from trial data · Jun 1, 2026 · Not medical advice
China